Evidence map›Paper›PMID 27216597›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2016

Original Research: Potential of urinary nephrin as a biomarker reflecting podocyte dysfunction in various kidney disease models.

Yusuke Wada, Masaki Abe, Hiroshi Moritani, Hikaru Mitori, Mitsuhiro Kondo, Keiko Tanaka-Amino, Megumi Eguchi, Akira Imasato, Yutaka Inoki, Hiroshi Kajiyama and 2 more

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yusuke WadaDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Masaki AbeDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan masaki.abe@astellas.com.
Hiroshi MoritaniDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Hikaru MitoriDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Mitsuhiro KondoDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Keiko Tanaka-AminoDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Megumi EguchiDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Akira ImasatoDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Yutaka InokiDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Hiroshi KajiyamaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama 3500495, Japan.
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama 3500495, Japan.
Yuichi TomuraDrug Discovery Research, Astellas Pharma Inc., Tasukuba-shi, Ibaraki 3058585, Japan.
Astellas Pharma (Japan) · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary nephrin is a potential non-invasive biomarker of disease. To date, however, most studies of urinary nephrin have been conducted in animal models of diabetic nephropathy, and correlations between urinary nephrin-to-creatinine ratio and other parameters have yet to be evaluated in animal models or patients of kidney disease with podocyte dysfunction. We hypothesized that urinary nephrin-to-creatinine ratio can be up-regulated and is negatively correlated with renal nephrin mRNA levels in animal models of kidney disease, and that increased urinary nephrin-to-creatinine ratio levels are attenuated following administration of glucocorticoids. In the present study, renal nephrin mRNA, urinary nephrin-to-creatinine ratio, urinary protein-to-creatinine ratio, and creatinine clearance ratio were measured in animal models of adriamycin nephropathy, puromycin aminonucleoside nephropathy, anti-glomerular basement membrane glomerulonephritis, and 5/6 nephrectomy. The effects of prednisolone on urinary nephrin-to-creatinine ratio and other parameters in puromycin aminonucleoside (single injection) nephropathy rats were also investigated. In all models tested, urinary nephrin-to-creatinine ratio and urinary protein-to-creatinine ratio increased, while renal nephrin mRNA and creatinine clearance ratio decreased. Urinary nephrin-to-creatinine ratio exhibited a significant negative correlation with renal nephrin mRNA in almost all models, as well as a significant positive correlation with urinary protein-to-creatinine ratio and a significant negative correlation with creatinine clearance ratio. Urinary protein-to-creatinine ratio exhibited a significant negative correlation with renal nephrin mRNA. Following the administration of prednisolone to puromycin aminonucleoside (single injection) nephropathy rats, urinary nephrin-to-creatinine ratio was significantly suppressed and exhibited a significant positive correlation with urinary protein-to-creatinine ratio. In addition, the decrease in number of glomerular Wilms tumor antigen-1-positive cells was attenuated, and urinary nephrin-to-creatinine ratio exhibited a significant negative correlation in these cells. In conclusion, these results suggest that urinary nephrin-to-creatinine ratio level is a useful and reliable biomarker for predicting the amelioration of podocyte dysfunction by candidate drugs in various kidney disease models with podocyte dysfunction. This suggestion will also be validated in a clinical setting in future studies.

Indexed as

AnimalsAnti-Glomerular Basement Membrane DiseaseBiomarkersCreatinineDiabetic NephropathiesDoxorubicinKidney DiseasesMaleMembrane ProteinsMiceMice, Inbred BALB CPodocytesPuromycin AminonucleosideRatsRats, WistarBiomarkersCreatinineDoxorubicinMembrane ProteinsnephrinPuromycin AminonucleosideanimalbiomarkersdiseasemodelsPodocyterenal

Identifiers

PMID27216597
PMCPMC5027945
OpenAlexW2520354422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.